China accuses Novartis of bribery

<p>A bribery claim has been made against Novartis.</p>

Novartis is at the centre of a bribery claim in China, just days after similar accusations were levelled against a company owned by Danone.

Alcon, the eye care unit of the firm, is accused by a Chinese newspaper of bribing doctors in 200 hospitals across the Asian nation.

Just a couple of weeks ago, the 21st Century Business Herald accused Novartis of bribing doctors in China to approve its products.

Chinese authorities also accused British drug giant GlaxoSmithKline of offering out bribes earlier in the summer.

Novartis strongly denied the claims, adding: "Alcon does not tolerate activities that are not in compliance with the laws and regulations in the markets where we operate."

Despite the bribery accusation, the share price of Novartis is slightly up today (September 18th). At 08:22 BST, its stocks were trading 0.29 per cent up for the day.

Danone also denied the bribery claims against it this week, with a spokeswoman for the firm saying: "Dumex Baby Food Co strictly adheres to Chinese laws and regulations."

Learn about the Asian markets and CFD trading at City Index

Build your confidence risk free
Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.